Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and